CRISPR Therapeutics AG (CRSP)
D
Pipeline Grade
Financial Position (from SEC Filings)
$344.9M
Cash & Equivalents
$108.9M
Quarterly Burn Rate
10 mo
Est. Cash Runway
$5,146M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-06-01 | Phase1 Readout | — |
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06208878 | A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies | OTHER | Enrolling By Invitation | 70 |
| NCT05643742 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies | PHASE2 | Recruiting | 120 |
| NCT07549698 | Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease | PHASE2 | Recruiting | 60 |
| NCT07491172 | A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias | PHASE1 | Recruiting | 90 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.